| |
|
|
| |
|
|
| |
HUM-MOLGEN
-> Events
-> Meetings and Conferences |
|
|
| |
| |
| |
May 09, 2023 |
|
|
| |
|
|
| |
|
|
|
Xtalks, online
2023 -5-31
Since the first therapeutic monoclonal antibody was approved by the US Food and Drug Administration (FDA) in 1986, the field of antibody therapy development has increased, yet it continues to face many challenges. The scarcity of antigen-specific B cells is one of the hurdles scientists face early-on when developing a monoclonal antibody to treat cancer, autoimmune disease or infection. In this webinar, learn about enhancing antibody discovery with novel strategies — such as the one developed by Single Cell Technology — that enable the accelerated generation of neutralizing monoclonal antibodies from influenza-vaccinated individuals.
Join this webinar to learn about the benefits of this approach for:
Expansion and activation of memory B cells
Isolation of antigen-specific memory B cells from vaccinated individuals with faster, gentler and safer microchip-based cell sorting
Capture and sequencing of antigen-specific antibodies using a novel platform for antibody discovery that uses next-gen sequencing technology
Creation, expression and cross-reactivity testing of recombinant antibodies
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
Chun-Nan Chen, Chief Executive Officer, Single Cell Technology Allison Schulkins, Chief Operating Officer, Single Cell Technology Crystal Montoya, Senior Marketing Product Manager, Miltenyi Biotec
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2023 -5-31
|
|
|
|
|
|
|
|
Registration:
|
|
Free registration
|
|
|
E-mail:
|
|
ajuurinen@xtalks.com
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp,
Frank S.
Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved.
Liability, Copyright and Imprint. |
|